Navigation Links
Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010
Date:10/18/2010

Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 -- DUBLIN, October 18, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010

 

DUBLIN, October 18, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce third quarter 2010 earnings on Friday 29 October, 2010.

Results press release will be 12:00 BST / 07:00 EDT issued at: Investor conference call 14:00 BST / 09:00 EDT time:

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:00 BST/9:00 EDT.

The details of the conference call are as follows: UK dial in: 0844-335-0351 US dial in: 1-866-8048688 or 1-718-3541175 International dial +44-844-335-0351 in: Password/Conf ID: 921 510 Live Webcast: http://www.shire.com/shireplc/en/investors

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details can be found on our Investor Relations website http://www.shire.com/shireplc/en/investors.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact: Investor Relations Souheil Salah (Rest of the World) +44-1256-894-160 Ricki Greenwood (North America) +1-484-595-8517
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Atrium Recognized by New Hampshire Bio/Medical Council
2. Shire Update on ProAmatine(R) (midodrine HCl)
3. Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide
4. Pentasa(R) - Shire Receives Ruling From FDA on Citizens Petition
5. Shire Purchases Strategic Site in Massachusetts
6. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
7. Area Residents Can Give a Little, Help A Lot at Shires BIG GIVE
8. Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
9. Excellent Results in a Transformational Year for Shire; Core Product Sales up 25%
10. Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
11. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 23, 2016 According to ... Development, Growth and Demand Forecast to 2022 - ... by Application (Drug Discovery and Development, Proteomics, Clinical ... Life Science and Biotechnology, Academic and Research Institute, ... the global mass spectrometry market was ...
(Date:5/23/2016)... -- The World Health Organization (WHO) expanded the Intended Use ... aged 13 years, and above. Effective immediately, the PrePex device, ... adolescent males in the 14 priority countries in Southern and ... male circumcision device to receive WHO Prequalification on 31 May ... said: " The expanded use of PrePex for ...
(Date:5/23/2016)... , UAE, May 23, 2016 ... importance of Precision Medicine and the role of ...   The First International Conference of VPS-Penn ... the distinguished patronage and presence of Sheikh Nahyan bin Mubarak ... focused in Precision Medicine, which helps provide personalized medicine and ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... i2i, a national leader in ... its “Transforming Outcomes” User Conference in Las Vegas on May 19-20, 2016. ... set the market standard for meaningful population health management. The company recently ...
(Date:5/24/2016)... ... 24, 2016 , ... Educational opportunities, and therefore life chances, ... communities providing richer opportunities. Recognizing the key role of housing in this system, ... school choice policies; (c) school desegregation policies; (d) wealth-focused policies; and (e) housing-focused ...
(Date:5/24/2016)... Georgia (PRWEB) , ... May 24, 2016 , ... Mental ... 1969 by the Church of Scientology and renowned professor of psychiatry Thomas Szasz, is ... of its “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening of ...
(Date:5/24/2016)... ... May 24, 2016 , ... Physical ... that focuses on repairing the musculoskeletal and neuromuscular systems of the human body ... restoration, NYDNRehab began providing treatments for physical therapy in New York, including ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... today announced the official relaunch of its community and education hub for women ... Eggsurance's mission is to create a safe and welcoming place for women to ...
Breaking Medicine News(10 mins):